Emily MenendeznccRCC | September 14, 2023
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | August 20, 2023
As one of the most aggressive forms of kidney cancer, there is a need for new treatment strategies for RMC.
Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Chung-Han Lee, MD, PhDASCO 2023 | June 16, 2023
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
Zachary BessetteASCO 2023 | May 26, 2023
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | May 18, 2023
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Zachary BessetteAUA 2023 | April 29, 2023
Dr. Rini provided an overview of nccRCC, including data pertaining to response to IO monotherapy and IO/TKI combinations.
Monty Pal, MDRoundtable | March 15, 2023
The panel shares how they treat frontline papillary kidney cancer.
Pavlos Msaouel, MD, PhDRenal Cell Carcinoma | March 10, 2023
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Zachary BessetteASCO GU Symposium 2023 | February 17, 2023
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.
Leah LawrenceRenal Cell Carcinoma | December 27, 2022
Nivolumab plus ipilimumab showed “modest clinical efficacy” in patients with nccRCC in a study of real-world data from ...
Hiten D. Patel, MD, MPHASCO GU Symposium 2021 | March 26, 2021
The phase 2 SWOG 1500 trial showed improvement in progression-free survival for cabozantinib in metastatic papillary RCC.